Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Convertible Debt (2022)

Coya Therapeutics (COYA) has disclosed Convertible Debt for 1 consecutive years, with $13.0 million as the latest value for Q4 2022.

  • Quarterly Convertible Debt changed N/A to $13.0 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $13.0 million through Dec 2022, changed N/A year-over-year, with the annual reading at $13.0 million for FY2022, N/A changed from the prior year.
  • Convertible Debt hit $13.0 million in Q4 2022 for Coya Therapeutics.
  • In the past five years, Convertible Debt ranged from a high of $13.0 million in Q4 2022 to a low of $13.0 million in Q4 2022.